NCT05502731 - Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

October 31, 2025

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Filgotinib

Filgotinib is a small molecule that reversibly inhibits Janus kinases (JAK, selectively JAK 1), thereby inhibiting downstream signalling events induced by various pro-inflammatory and regulatory cytokines.

DRUG

Adalimumab

Adalimumab is a monoclonal antibody selectively inhibiting the pro-inflammatory cytokine TNF-alpha.

Trial Locations (1)

2300RC

Leiden University Medical Center, Leiden